Are ‘Turbo Cancers’ Real? An Evidence Review of Early-Onset and Aggressive Cancer in 2026

By Editorial Team -

By OneDayMD Editorial Team · Originally published November 2024 · Last updated October 28, 2026 · Sources reviewed through October 28, 2026 · Next scheduled review: January 2027

Quick answer: are “turbo cancers” real? Early-onset cancers (diagnosed before age 50) are rising, and clinicians do see rare, fast-progressing cases. A vaccine-driven “turbo cancer” is not established. The best evidence is observational cohorts (Tier 2) plus case and mechanistic reports (Tiers 3–4) showing temporal association, not causation. A narrative review published October 15, 2026 in the Journal of Toxicology lists cancer as an open question. This article is educational, not medical advice. It does not conclude that COVID-19 vaccines cause cancer in any individual or population.
What changed in this update (October 21, 2026)
  • Added the Quinn et al. 2026 Journal of Toxicology review, with its cancer-relevant content and limits.
  • Merged duplicate entries (the 2025 transcriptomic preprint and its published version) and replaced social-media case narratives with one graded evidence table.
  • Fixed the internally contradictory conclusion, and corrected the 2022 early-onset cancer report’s journal name (Nature Reviews Clinical Oncology).
  • Added the October 19, 2026 VAX-CAN research proposal, the Korean cohort’s Expression of Concern and published critiques, and corrected the Kuperwasser & El-Deiry figures (69 publications, 333 patients).
  • Removed named private individuals, an unsupported “impossible” biology claim, and “shedding” and prophylaxis claims; added FAQ, AI guide and schema.

Evidence key: Tier 1 randomized trial or systematic review · Tier 2 observational cohort · Tier 3 laboratory or mechanistic · Tier 4 case report, narrative review or expert opinion.

What is a “turbo cancer”?

“Turbo cancer” is not a formal diagnosis. It is shorthand for cancers that present late, grow unusually fast, appear in younger adults, or return soon after remission. The related oncology term, hyper-progression, was first described in patients treated with immune checkpoint inhibitors.

The public debate over a possible vaccine link began in 2022, when The Atlantic reported Belgian immunologist Michel Goldman’s lymphoma, which he suspected was accelerated by vaccination and boosting. Hematologist-oncologist Vinay Prasad criticized the coverage, arguing that case reports are not evidence and that epidemiological data are needed before such concerns are raised.

Is early-onset cancer really rising?

Yes, and the rise began before 2020. A 2022 review in Nature Reviews Clinical Oncology (Ugai et al.) documented increasing incidence of cancers diagnosed before age 50. Yale Cancer Center and Smilow Cancer Hospital now run an Early Onset Cancer Program for patients aged 18–49.

Dr. Harvey Risch (Yale School of Public Health, emeritus) said in 2023 that clinicians were seeing unusually aggressive colorectal cancers in adults as young as 25. This is an expert report, not published incidence data. Dr. Veda Giri, who directs the Yale program, reportedly found about 1,300 early-onset breast and 600 gastrointestinal cancer cases in two years of Smilow records (relayed by Cancer Active; reference 19). Whether pandemic-era infection or vaccination added to the trend is unproven.

What the October 2026 Journal of Toxicology review says about cancer

Short answer: Quinn et al. is a 16-author narrative review of modified-mRNA vaccine toxicology, published October 15, 2026 (open access, Wiley). It lists a potential association with cancer and reports of possible genomic integration among 11 unresolved questions. It presents no new cancer-incidence data and does not claim causation. Evidence: Tier 4.

Cancer-relevant content

  • Residual DNA: cites independent reports of residual plasmid DNA in some Pfizer lots at 36–627 times regulatory limits, including SV40 promoter/enhancer sequences, and critiques that qPCR underestimates DNA impurities compared with fluorometry. The authors acknowledge the extent of SV40 contamination is still debated.
  • Genomic integration: notes one reported case of apparent integration of vaccine-derived sequences alongside aggressive cancer and states it needs independent confirmation.
  • Spike-protein hypothesis: summarizes proposals that spike exposure could contribute to cancer indirectly, through p53 interference, chronic inflammation and immune dysregulation (a “multi-hit,” non-genotoxic model).
  • Transcriptomics: cites von Ranke et al. (World J Exp Med 2025) on gene-expression changes in people with new adverse events or cancer after vaccination. This is the same small dataset covered below, not an independent replication.
  • Lymph nodes: reports reactive lymphadenopathy in 11% and 16% of breast-screening participants after doses one and two, versus a background under 0.05%. Editorial note: swollen nodes are a known, usually benign vaccine effect, so imaging findings need clinical correlation (the National Cancer Institute makes the same point [15]).
  • Research design: recommends prospective cohorts with serial biomarkers and biobanking.

Limits to weigh

  • It is a narrative review (snowball sampling via Google Scholar and PubMed), with no original data and no formal risk-of-bias appraisal.
  • Several authors disclose roles in independent groups that publish on mRNA vaccine safety (HART, CERES, MWGFD).
  • Its mortality estimates are described by the authors as speculative and include a non-peer-reviewed source.
  • It was published six days before this update; independent expert commentary is still pending.

Evidence at a glance

No study in this table shows that a COVID-19 vaccine causes cancer. The strongest signals are Tier 2 observational cohorts, which can reflect confounding, detection bias and short follow-up.

Quinn et al., J Toxicol 2026 [1] Tier 4
Design: Narrative review, no original data
Reported finding: Cancer association and genomic integration listed as unresolved; calls for prospective surveillance
Key limits: Selective sampling; secondary citation of other studies
Kuperwasser & El-Deiry, Oncotarget 2026 [2] Tier 4
Design: Scoping review of published reports: 69 publications, 333 patients
Reported finding: Cancers or progression occurring after vaccination or infection; authors state neither this nor the cohort studies show causation; many sources are single case reports
Key limits: No denominator; publication bias; cannot estimate risk
South Korea cohort, Biomarker Res 2025 [3] Tier 2
Design: Retrospective national cohort, ~8.4 million adults, 1-year follow-up
Reported finding: Hazard ratios: overall 1.27; lung 1.53; prostate 1.69; thyroid 1.35; gastric 1.34; colorectal 1.28; breast 1.20
Key limits: Observational; short window. Under a journal Expression of Concern; critics cite surveillance (screening) bias and matching problems [3]
Italian cohort, EXCLI J 2025 [4] Tier 2
Design: Regional cohort, ~296,000 people, 30 months
Reported finding: Overall cancer +23%; breast +54%, bladder +62%, colorectal +35% (significant); other sites not significant
Key limits: Observational; authors note healthy-vaccinee bias; screening differences possible
Bladder cancer case, IJIRMS 2025 [5] Tier 4
Design: Single case with genomic analysis
Reported finding: 31-year-old woman, stage IV bladder cancer within 12 months of three Moderna doses; authors report a plasmid-derived spike gene fragment integrated in tumor DNA
Key limits: n=1; authors call for long-read sequencing and cohort studies
von Ranke et al., World J Exp Med 2025 [6] Tier 3
Design: Blood RNA-seq: 3 with adverse events, 7 with new cancers
Reported finding: Signatures of mitochondrial, immune and proliferative dysregulation
Key limits: Very small sample; earlier preprint was withdrawn from Preprints.org
Leukemia metabolomics, Curr Mol Med 2025 [7] Tier 3
Design: Bone marrow: 7 vaccinated leukemia, 2 unvaccinated leukemia, 7 healthy
Reported finding: Extra metabolite changes in the vaccinated leukemia group; onset 15–63 days after vaccination
Key limits: n=16; timing alone does not show cause
Marik & Hope, J Indep Med 2025 [8] Tier 3–4
Design: Mechanistic hypothesis paper
Reported finding: Five proposed pathways (metabolic reprogramming, stem-like cells, apoptosis resistance, angiogenesis, immune dysfunction)
Key limits: No patient-level data; check author and publisher affiliations
Belgian mouse report, Front Oncol 2023 [9] Tier 3
Design: 1 of 14 mice
Reported finding: One mouse died two days after a booster; lymphoma found in several organs
Key limits: Single animal
Case reports: JAMA 2022 [10]; Medicina 2023 [11]; JEADV 2022 [12] Tier 4
Design: Case reports
Reported finding: Invasive breast cancer ~6 months after post-vaccine lymphadenopathy (39-year-old); stage 2 NHL after nodes appeared 10 days post dose 3 (66-year-old, plus 8 similar cases in a literature review); DLBCL in 2 patients
Key limits: Small numbers; coincidence cannot be excluded
Nature 2025 [13] Tier 2–3
Design: Retrospective patient analyses with mechanistic work
Reported finding: mRNA vaccination associated with better immunotherapy outcomes in lung cancer and melanoma (opposite direction)
Key limits: Retrospective; confounding possible

The June 3, 2026 U.S. Senate subcommittee hearing on this topic [14] is testimony (Tier 4) and is not graded above.

Case reports, testimonials and what we left out

Social-media case posts are not evidence and were removed from this version. Earlier versions reproduced clinicians’ posts naming individual patients, claims about “sudden deaths” of physicians, and an ivermectin–fenbendazole testimonial. These lacked records, denominators or independent verification. In the testimonial, chemotherapy was given at the same time, so tumor-marker changes cannot be attributed to the repurposed drugs, and we know of no randomized trial supporting them in colorectal cancer.

The 2025 Marik and Hope mechanisms paper is summarized in the table above; see our detailed article. Related: 17 proposed mechanisms , Turbo cancer fact check and Long COVID and cancer risk.

Counterarguments

  • Institutional positions: the Mayo Clinic, National Cancer Institute and Global Vaccine Data Network describe “turbo cancer” as unsubstantiated, citing no causal evidence in large-scale surveillance. The NCI states there is no evidence that COVID-19 vaccines cause cancer, recurrence or progression [15].
  • Korean cohort status: the journal posted an editorial notice on October 22, 2025 saying concerns had been raised, and a later commentary describes an Expression of Concern. Published critiques (including a Belgian correspondence in Frontiers in Public Health [16]) argue that screening intensity, socioeconomic factors and short follow-up could explain the associations. We found no retraction, so the paper stays in the table with this caveat.
  • Registries: SEER and GLOBOCAN data have not shown a vaccine-attributable spike, and the early-onset rise predates the pandemic. Proposed drivers include obesity, alcohol and sedentary lifestyles.
  • Cohort limits: reported hazard ratios can arise from detection bias, healthcare-seeking behavior and short follow-up. Healthy-vaccinee bias can distort results in either direction: the Italian authors argue it hides risk, while critics argue it and similar confounders can inflate cancer estimates.
  • Opposite signal: the 2025 Nature work associates mRNA vaccination with better immunotherapy outcomes in some cancers.

What would settle the question

  • Prospective cohorts with serial biomarkers and biobanking (the Quinn review’s proposal).
  • Registry linkage with vaccination records, adjusted for age, stage and screening intensity.
  • Independent replication of integration findings, using long-read sequencing and matched unaffected controls.
  • A standard definition of “turbo cancer” based on measured tumor growth rate before and after exposure.

VAX-CAN proposal. On October 19, 2026 our own research team published VAX-CAN, a concept white paper (v1.2) for an independently funded programme: a randomized biomarker study only where ethically justified, a prospective cancer-incidence cohort, and a separate surveillance cohort for cancer survivors, using ctDNA and exploratory multi-cancer early detection (MCED) tests. It states that it does not assume vaccines cause cancer, would replace “turbo cancer” with prespecified endpoints (incident cancer, confirmed recurrence, objective progression, confirmed molecular signal), and would publish all results. Cautions: it is not approved by an ethics committee, funded, registered or started; MCED tests have no proven mortality benefit and can produce false positives; and clonal hematopoiesis can mimic tumor DNA in blood tests. Disclosure: this is a OneDayMD proposal, not independent evidence (Tier 4).

What to do now

  • Keep age-appropriate screening and see a clinician for persistent warning signs: unexplained weight loss, rectal bleeding or bowel changes, a new breast lump, drenching night sweats, or lymph nodes that keep growing.
  • Swollen nodes after vaccination are common. Nodes that persist or enlarge should be evaluated.
  • Any postmenopausal bleeding needs evaluation, whatever the cause.
  • If you have cancer, follow your oncology team’s plan and do not delay surgery or treatment because of this debate.
Supplement note (affiliate). Some clinicians propose nattokinase, bromelain and curcumin to support clearance of persistent spike protein. Laboratory data exist (Tier 3), but no trial shows these products prevent or treat cancer, and they can affect clotting, so discuss them with your oncology team, especially around chemotherapy or surgery. See our evidence-tiered review. Affiliate link: The Wellness Company Base Spike Detox (code ONEDAYMD).

Using this article with AI assistants

Paste the article URL or text, then try one of these. AI tools can misstate statistics, so verify against the references and your clinician.

  • Claude: “For each study in the evidence table, explain what design it used, what it can and cannot show, and what to ask my oncologist about it.”
  • ChatGPT: “Turn the evidence table into a one-page summary I can bring to an appointment, keeping the tier labels.”
  • Gemini: “Compare this article’s claims with current NCI and American Cancer Society statements on early-onset cancer.”
  • Perplexity: “Find independent commentary on the 2026 Journal of Toxicology review and the South Korea cohort, with sources.”

Conclusion

Current evidence, including the detailed mechanisms and case syntheses from Marik and Hope, supports temporal associations between COVID-19 vaccination and aggressive cancers but does not substantiate "turbo cancer" as a proven post-vaccine phenomenon. While mainstream discourse has largely dismissed these cancers as coincidental or biologically implausible, the mechanistic data presented in the review by Marik and Hope suggest otherwise. 

The SARS-CoV-2 spike protein may interfere with core regulatory pathways of carcinogenesis, including metabolic reprogramming, immune surveillance, apoptosis resistance, and stem cell proliferation. Additional mechanisms such as EBV reactivation, SV40 DNA sequences, reverse transcription, and codon optimization may further contribute to genomic instability and oncogenic transformation. Given the consistent temporal association and biological plausibility, it is imperative to investigate these phenomena with objectivity and scientific rigor. 
Proactive risk stratification, enhanced postvaccination surveillance, and early, targeted prophylactic strategies, such as the ROOT4 protocol, may help mitigate the potential impact of these malignancies.
The rise in early-onset cancer is a valid clinical and public health issue backed by long-term data. However, current science does not support vaccines as a causal factor in cancer development. Reports of temporal association alone are not sufficient to infer causation. Rigorous, controlled studies and long-term surveillance are required to understand any true relationships between immune activation (from infection or vaccination) and cancer biology.

If you developed symptoms you didn’t have before your shot, we would encourage you to seek out expert help. For those concerned about persistent spike protein, some clinicians have proposed detox protocols involving nattokinase, bromelain, and curcumin to support the body's natural repair mechanisms.

FAQ

Are turbo cancers real?
Rapidly progressing cancers and rising early-onset cancers are real and documented. “Turbo cancer” is a non-clinical label, and a vaccine-caused form has not been proven. Evidence so far is temporal association in observational cohorts, case reports and mechanistic studies, which cannot establish causation.

Is the rise in early-onset cancer caused by COVID-19 vaccines?
Not shown. Early-onset cancer incidence was rising before 2020. Mainstream institutions report no vaccine-attributable spike in registries, while some cohort studies report higher hazard ratios that remain open to bias and confounding.

What does the October 2026 Journal of Toxicology review conclude about cancer?
The narrative review by Quinn and colleagues lists a potential cancer association and possible genomic integration among 11 unresolved questions and calls for further investigation and prospective surveillance. It reports no new incidence data and does not claim proven causation.

Should I skip screening or delay cancer treatment because of this debate?
No. Early detection and standard treatment remain the best-supported approach for every cancer. Discuss any concerns, supplements or vaccination questions with your treating oncology team.

Do spike detox supplements prevent or treat cancer?
Nattokinase has laboratory evidence of spike-degrading activity (Tier 3), and these supplements can affect clotting. Check with your clinician before use, especially during cancer treatment.

References

  1. Quinn GA, Bagus P, et al. Toxicological vulnerabilities and emerging safety signals in modified mRNA vaccine technology. J Toxicol 2026;2026:8202757. doi:10.1155/jt/8202757 · PMC full text
  2. Kuperwasser C, El-Deiry WS. COVID vaccination and post-infection cancer signals. Oncotarget 2026. PubMed · PMC
  3. South Korea national cohort, Biomarker Research 2025. Our summary · Journal page with editorial notice
  4. Italian population cohort, EXCLI J 2025. PubMed
  5. Genomic integration and stage IV bladder cancer case report, Int J Innov Res Med Sci 2025. Article
  6. von Ranke NL, et al. Synthetic mRNA vaccines and transcriptomic dysregulation. World J Exp Med 2025;15(4):113869. Article
  7. Metabolomic profiling of leukemic hematopoiesis after BNT162b2, Curr Mol Med 2025. PubMed
  8. Marik P, Hope J. Mechanisms of post-mRNA vaccine “turbo cancer.” J Indep Med 2025. Article
  9. Belgian mouse lymphoma report, Front Oncol 2023. PMC
  10. Vaccination-associated lymphadenopathy then breast cancer, JAMA 2022. Article
  11. Non-Hodgkin lymphoma case and review, Medicina 2023. PubMed
  12. Diffuse large B-cell lymphoma letter, J Eur Acad Dermatol Venereol 2022. Article
  13. mRNA vaccination and immunotherapy outcomes, Nature 2025. Article
  14. U.S. Senate Permanent Subcommittee on Investigations hearing, June 3, 2026. Hearing record
  15. National Cancer Institute. COVID-19 vaccines and people with cancer. NCI guidance. (Mayo Clinic and Global Vaccine Data Network statements: add direct links before publishing.)
  16. Critical appraisal of Kim et al., Front Public Health 2026 (University of Namur and collaborators). PDF copy
  17. VAX-CAN: an independent study of COVID-19 vaccination, circulating tumour DNA and cancer outcomes (concept white paper v1.2), OneDayMD, October 19, 2026. Article
  18. Ugai T, et al. Is early-onset cancer an emerging global epidemic? Nat Rev Clin Oncol 2022;19:656–673. doi:10.1038/s41571-022-00672-8
  19. Yale experts see rise in younger, turbo cancer. Cancer Active, 2024. Article

    The Wellness Company's Ultimate Spike Detox


    The first ever spike detox protocol appeared in the US Medical Literature and now it is available to you!

    This base spike protein detox protocol consists of these three powerful ingredients: Spike Support's Nattokinase, Bromelain, and Tumeric Extract.

    Vaccinated or not, prioritizing your well-being has never been more crucial.

    Buy this ultimate detox bundle today, researched by Dr. Peter McCullough.

    Recommended to maintain daily health for anyone exposed to COVID, vaccines, or shedding – and may help your body repair itself and remain at optimal health.

    Where to buy Base Spike Detox Trio Formula: Available on The Wellness Company's website: Ultimate Spike Detox.

    Disclaimer: This article does not make a determination on whether COVID‑19 vaccination causes cancer in any individual or population — that question remains genuinely contested among credentialed researchers, as documented above, and is not something this article, or any single study cited in it, resolves on its own. If you are a cancer patient or caregiver, please make treatment decisions with your treating oncology team.

    Comments

    1. AnonymousOctober 5, 2025 at 9:58 AM

      Its in the blood. Full blood transfusion. Get rid of the bad blood and replace with healthy blood that hasn't been reprogrammed by the vaccine.

      ReplyDelete

    Post a Comment

    Popular posts from this blog

    Dr Peter McCullough: How to Detox Spike Protein from Body (2026 Update)

    By Editorial Team -
    Image
    Base Spike Detox According to Dr Peter McCullough (in a X/Twitter post): Base Spike Detox is what I am currently using in my practice for those who have had COVID-19 multiple times, one or more of the COVID-19 vaccines, or both and believe persistent SARS-CoV-2 Spike protein could be causing problems in their body.  I have arrived, based on the emerging scientific literature (1) and my clinical observation, that three OTC products are essential as a triple base combination: Nattokinase 2000 FU (100 mg) twice a day  — take on an empty stomach Bromelain 500 mg once a day  — take on an empty stomach Nano/Liposomal Curcumin 500 mg twice a day  — take with food How long should I take this? Dr. McCullough recommends a minimum of 3 months , with many patients requiring 6–12 months or longer. Progress can be tracked via a spike protein antibody test (available through Labcorp in m...
    Read more

    Dr. Peter McCullough's Spike Protein Detox Protocol: Base Spike Detox Explained (2026)

    By Editorial Team -
    Image
    An evidence-tiered review of the nattokinase, bromelain and curcumin regimen proposed by Dr. Peter McCullough: what it is, what the research does and does not show, how to use it safely, and how (not) to monitor it. By OneDayMD Editorial Team | Originally published March 2026 | Last updated October 18, 2026 | Sources reviewed through October 2026 | Next scheduled review: April 2027 Quick answer The McCullough Base Spike Detox is a clinician-proposed regimen of nattokinase (2,000 FU twice daily), bromelain (500 mg daily) and nano/liposomal curcumin (500 mg twice daily) intended to break down persistent SARS-CoV-2 spike protein. [1] Laboratory studies show nattokinase can degrade spike protein in cell and test-tube systems TIER 3 [2] [3] , and spike antigen does persist in a minority of people for months after infection TIER 2 [8] . Nattokinase and bromelain affect clotting, and highly bioavailable curcumin has been linked to rare liver injury, so check with a physician fi...
    Read more

    Dr Peter McCullough: How to Measure Your Spike Protein Antibody (2026)

    By Editorial Team -
    Image
    Dr. McCullough explained (1) that the spike protein is an engineered, synthetic molecule roughly 1,200 amino acids long and resistant to degradation by the body’s normal proteases. He described how the protein was modified in laboratory settings (notably at the Wuhan Institute of Virology) to tightly bind to the ACE2 receptor, which is found throughout the body—in the lungs, heart, endothelium, kidneys, and brain. Because this receptor regulates angiotensin metabolism, older individuals with fewer ACE2 sites catabolize the spike less efficiently, leading to worse outcomes. Whether introduced by infection or by genetic‑code‑based vaccines, McCullough asserted, the persistent spike damages tissues directly and through chronic inflammation, micro‑clotting, and autoimmune cross‑reactivity. Spike Protein Protocol Personalizer Based on Dr. Peter McCullough's Base Spike Detox & FLCCC I-Recover Frameworks ⚠ Medical Disclaimer: This tool is...
    Read more

    Long COVID Treatment 2026: The Complete Evidence Guide

    By Editorial Team -
    Image
    By OneDayMD Editorial Team · Published September 30, 2026 · Updated October 2026   Quick Answer: does anything work for Long COVID? No specific treatment has been proven to work for Long COVID in general. Randomized trials have found no benefit from extended Paxlovid (959 adults), metformin (396) or short-course hyperbaric oxygen (80). Promising but unconfirmed signals include the SIM01 synbiotic (463 people, Hong Kong), physical-activity coaching (50) and the Ultimate Spike Detox. For prevention during acute COVID, Paxlovid (144 people) and metformin show mixed or underpowered results. Care remains individualized and symptom-focused. Medical disclaimer. This article is educational and is not personal medical advice, diagnosis or treatment. Long COVID can overlap with cardiovascular, pulmonary, neurological, endocrine and sleep disorders. Do not start, stop or change pres...
    Read more

    FLCCC I-CARE Treatment Protocol for Flu and RSV: What the Evidence Shows (2026–27 Update)

    By Editorial Team -
    Image
    By OneDayMD Editorial Team | Originally published May 2023 | Last updated October 2026 | Sources reviewed through October 2026 Quick Answer The FLCCC/IMA I-CARE Flu and RSV protocol is a home regimen of nasal and mouth antiseptics, supplements and off-label drugs. Most components are supported by laboratory or expert-opinion evidence, not influenza trials. The best-evidenced treatments for influenza are prescription antivirals started early: oseltamivir for hospitalized patients and baloxavir or oseltamivir for high-risk outpatients. Seek care promptly if you are high-risk or struggling to breathe. What changed in this update (October 2026) Fixed copy-paste wording that described the protocol as a COVID-19 guide. Replaced the claim that Tamiflu has “no antiviral properties.” Oseltamivir is a direct-acting neuraminidase inhibitor, and the 2025 paper is in JAMA Ne...
    Read more

    Possible Pneumonic Plague Case in Siberia: What We Know About the Irkutsk Incident

    By Editorial Team -
    Image
    A laboratory worker at an anti-plague research institute in Siberia died after developing severe pneumonia. Russian authorities have not confirmed plague , while conflicting reports have fueled concern about a possible pneumonic-plague infection or laboratory exposure. Updated: October 6, 2026   |   Status: Developing story Important: There is no confirmed evidence, as of October 6, 2026, that a pneumonic-plague outbreak is occurring in Siberia. Russia's federal public-health watchdog, Rospotrebnadzor, has described the patient's illness as pneumonia of unknown etiology and said expanded testing did not identify microorganisms associated with her professional activity. The World Health Organization has said that, based on available information, the public-health risk to the general population appears low. What happened in Irkutsk? A 28-year-old employee identified by local and international reporting as Da...
    Read more

    Fact Check: Unpacking the Spike Protein Debate (2026)

    By Editorial Team -
    Image
    Medically reviewed by: OneDayMD Editorial Team | Last updated: August 2026 Introduction The rapid development and deployment of COVID-19 vaccines have been monumental in combating the global pandemic, saving countless lives and enabling societies to regain a sense of normalcy. Central to the efficacy of many of these vaccines, particularly mRNA and viral vector-based ones, is the spike protein—a key component of the SARS-CoV-2 virus that facilitates its entry into human cells. By instructing the body to produce a version of this protein, vaccines train the immune system to recognize and neutralize the virus without causing illness. However, as vaccination campaigns expanded, so did public curiosity and concern about the spike protein's role, fueled by a mix of scientific complexity, misinformation, and distrust. For years, the public was told that COVID-19 mRNA vaccine components degraded rapidly—within days to weeks. Hulscher, McCullough, and colleagues' ...
    Read more

    Dr Peter McCullough: Povidone Iodine, Oral and Nasal Hygiene (2026)

    By Editorial Team -
    Image
    Dr. Peter McCullough is an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas, USA. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. McCullough Protocol 2022 Update: Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial ( JAMA 2025 ) Everyone is familiar with nasal and oral swab testing for COVID-19. It should be obvious the virus is replicating in the nose, and with Omicron, the speed of replication has become much greater than the prior strains of the virus. Thus, there is a wonderful opportunity to reduce viral replication, in fa...
    Read more

    How We Can Heal From the COVID-19 Vaccines?: I-Recover Protocol and McCullough Base Spike Detox — Definitive 2026 Guide

    By Editorial Team -
    Image
    Immune Systems Advisor · Integrative Medicine White Paper · Open Access Authors: OneDayMD Editorial Team (synthesis and editorial adaptation) · Original protocols: Marik P, Kory P (IMA/FLCCC, 2022–2024); McCullough PA (Cureus, 2023) · Published: March 2023 · Last updated:  August 2026 Evidence Tier Key:   TIER 1 RCT / systematic review   TIER 2 Observational / cohort   TIER 3 In vitro / mechanistic   TIER 4 Expert consensus / clinical observation ⚠ Medical Disclaimer — Please Read First. This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The protocols described involve supplements with significant anticoagulant activity. Always consult a licensed physician before starting, especially if you take blood thinners, are pregnant or breastfeeding, have a bleeding disorder, or are treating a child. For a virt...
    Read more

    Find a Doctor to prescribe Hydroxychloroquine, Ivermectin and Early Outpatient Treatments

    By Editorial Team -
    Image
    Medical Disclaimer: This directory is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or prescription medication. Directory: Find Early Outpatient COVID-19 Telemedicine Doctors & Prescribers Treatment decisions should be made in consultation with a licensed healthcare professional based on clinical evaluation as early as possible after symptom onset. Below is an updated directory of licensed physicians, clinics, and nationwide telemedicine providers offering outpatient consultations, early treatment evaluations, and custom health protocols. Related: How to Get Ivermectin in the US : Pharmacies, Legal Status & State-by-State Access (2026) Multi-State & Nationwide Telemedicine Services The following medical organizations and licensed practices offer virtual healthcare consultations across multiple states: ...
    Read more

    Labels

    Show more